Author: Gary Johnson, Chief Growth Officer, Curae
Published: 07/16/2026 | Last Reviewed: 07/13/2026
Reading Time: Approximately 10 minutes
Recourse debt in healthcare requires health systems to maintain balance-sheet reserves against potential repurchase obligations and may trigger bond-covenant restrictions that affect debt-service coverage ratios and credit ratings. Non-recourse debt permanently transfers all repayment risk to the financing company, eliminating reserve requirements and covenant exposure entirely. For health systems operating on the 1% to 3% operating margins that Kaufman Hall identifies as the norm across U.S. hospitals, the choice between recourse and non-recourse patient financing is not an accounting detail. It is a material financial risk management decision that belongs on the CFO’s desk. CURAEPay, the patient payment financing solution within Curae’s Patient Financial Access Platform, operates on a fully non-recourse model, funding the patient’s responsibility upfront within 48 hours, with no balance-sheet exposure or reserve requirements for the health system.
Patient financing has historically been treated as a revenue cycle function. The billing department selects a vendor; patients are offered a payment option, and the arrangement is managed downstream. That process made sense when patient financial responsibility represented a small and relatively predictable share of total health system revenue. That is no longer the scenario. According to the Healthcare Financial Management Association, patient responsibility now represents more than 30% of total net patient revenue and is growing. With 41% of American adults carrying healthcare debt and 1 in 3 hospitals reporting bad debt exceeding $10,000 per patient case, the structure of a patient financing arrangement has direct implications for balance-sheet treatment, bond covenant compliance, reserve requirements, and operating margin.The specific question a CFO should be asking is this: when your health system enters a patient financing arrangement, who carries the risk if the patient does not pay? The answer to that question determines whether your financing program is a revenue recovery tool or a contingent liability.This article explains the financial mechanics of recourse and non-recourse debt, presents eight dimensions most relevant to health system financial leadership, and explains why the decision matters more in 2026 than it ever has before.
Every patient financing arrangement involves three parties: the patient, the health system, and the financing company. The fundamental question in any financial arrangement is which party bears the risk if the patient fails to repay.
In a recourse arrangement, the health system transfers patient receivables to a financing or collection company but retains contingent liability for those accounts. If the patient does not repay, the health system may be required to repurchase the account, refund a portion of the advance, or absorb a reserve charge against future advances. The risk has only been temporarily and conditionally transferred.
In a non-recourse arrangement, the financing company purchases the patient receivable and assumes all credit risk associated with that account. If the patient does not repay, the financing company absorbs the loss. The health system retains the revenue it received and has no further financial obligation related to that account. The risk has been transferred permanently and completely. Even with a non-recourse patient financing program, the performance matters as measured by the total patient revenue gained. More to come on this point later in this article.
The financial consequences extend well beyond collection performance. They reach into balance-sheet treatment, bond-covenant compliance, reserve methodology, and the debt-service coverage calculations that bond rating agencies use when evaluating health system creditworthiness.
Under Generally Accepted Accounting Principles (GAAP), a health system that enters a recourse-based patient financing arrangement may be required to recognize a contingent liability on its balance sheet. That liability depends on the recourse structure, the volume of patient accounts financed, and the historical default rate on those accounts.
For health systems with modest operating margins, the reserve requirement associated with a recourse portfolio can represent a meaningful drag on financial ratios. Reserves reduce net assets, which affects equity calculations and, in turn, debt-to-equity ratios that lenders and rating agencies monitor.
The reserve calculation is not static. Rising patient responsibilities are driven by higher deductibles due to HDHP adoption by employers at a higher rate, and expiring ACA subsidies causing patients to trade down/choose Bronze plans with higher deductibles. A health system that entered a recourse financing arrangement under one set of economic conditions may find that the reserve obligation has grown materially as the patient financial environment has deteriorated.
Non-recourse financing eliminates this dynamic entirely. Because the financing company has assumed all credit risk, the health system has no contingent liability to reserve against. The transaction is clean from a balance-sheet perspective; receivables are converted to cash, and no offsetting liability is created
For health systems with publicly issued debt, the distinction between recourse and non-recourse financing has direct implications for compliance with bond covenants. Most hospital bond indentures include financial covenants that specify minimum thresholds for metrics such as days cash on hand, debt service coverage ratio (DSCR), and operating margin. Covenant violations can trigger technical defaults, accelerated repayment obligations, or restrictions on new borrowing.Recourse-based financing arrangements create two covenant risks that non-recourse arrangements avoid.
The first is the contingent liability risk described above. If a recourse portfolio generates reserve requirements that reduce net assets, the resulting impact on debt-to-equity ratios can push a health system toward covenant thresholds it would otherwise clear comfortably.
Second is the risk of cash flow timing. Under a recourse arrangement, the health system may be required to return funds to the financing company if recourse is triggered. This creates unpredictable cash outflows that complicate debt service coverage calculations. A health system that projects DSCR based on collected patient revenue may find that recourse repurchase obligations reduce the actual cash available for debt service below the projected figure.
Non-recourse financing eliminates both risks. There are no contingent liabilities to reserve against or recourse repurchase obligations to disrupt cash flow projections. For health systems operating on thin margins and managing bond covenants, this is a practical risk management consideration that belongs in every financing vendor evaluation.
The table below summarizes the eight financial dimensions most relevant to CFOs and revenue cycle leadership when evaluating patient financing structures.
Dimension |
Recourse Financing |
Non-Recourse Financing |
Balance Sheet Treatment |
Requires reserves for potential repurchase obligations |
No reserve requirement |
Bond Covenant Risk |
May trigger restrictions on outstanding obligations |
No covenant impact |
Provider Financial Liability |
Provider liable if patient defaults |
Liability transfers fully and permanently to financing company |
Patient Eligibility Rate |
Often limited to lower-risk credit profiles |
90%+ of patients eligible (CURAEPay) |
Revenue Timeline |
Revenue at risk until patient repays |
Full upfront funding within 48 hours |
Pricing Structure |
Variable, based on AR purchase discount |
Platform fee representing a fraction of recovered revenue |
Implementation Timeline |
Complex integration often required |
Under 45 days |
Patient Brand Impact |
May carry third-party card branding |
Provider-branded loyalty product |
Each dimension in this table represents a category of risk. The recourse column describes a financing structure that creates contingent liability, delays revenue recognition, limits patient reach, and redirects patient loyalty to a third-party brand. The non-recourse column describes a structure that eliminates contingent liability, accelerates revenue, reaches 90%+ of patients, and builds loyalty to the health system’s own brand.
The eligibility rate comparison above deserves specific attention, because it is frequently overlooked in CFO-level financing evaluations.A patient financing platform that approves 60% of applicants has the potential to convert 60% of patient balances into funded receivables (to avoid bad debt). The remaining 40% will either enter collections, age into write-offs, or create charity care obligations. For a health system with $50 million in annual patient financial responsibility, the difference between a 60% approval rate or eligibility rate and a 90% approval rate/eligibility rate is $15 million in potential additional funded receivables per year.
CURAEPay’s 90%+ applicant approval rate is achieved by extending financing to patients with limited or challenged credit histories. These are patients that standard medical credit card underwriting would decline. This is possible because the CURAEPay patient financing solution has a proprietary method to assess repayment risk and structure the revolving line of credit. Curae’s credit lines are issued by The Bank of Missouri, and the accounts are serviced by Atlanticus Holdings Corporation (Nasdaq: ATLC), which has more than 28 years of consumer credit and revenue-cycle FinTech experience. The financing company’s ability to absorb credit risk across a broad patient population is what makes broad eligibility economically viable. This approach makes non-recourse financing structurally superior to recourse arrangements for health systems seeking to maximize funded receivables.
The financial case for non-recourse patient financing has always been strong, but in 2026 the policy environment is making it urgent.Three federal policy shifts are simultaneously expanding patient financial responsibility, and each one increases the default risk embedded in recourse-based patient financing portfolios.
The IRS raised the HDHP out-of-pocket maximum to $17,000 for family coverage in 2026, up from the prior-year limit. Patients facing these limits need financing and those who cannot access financing or provide the funds on their own, become bad debt. Under a recourse arrangement, the health system retains contingent liability for that bad debt even after it has been financed. Under a non-recourse arrangement, the financing company absorbs that liability entirely.
Enhanced ACA premium tax credits expired on December 31, 2025. The Congressional Budget Office estimated that expiration would result in premium increases of 50% or more for many Marketplace enrollees. Driving a wave of coverage lapses and creating additional self-pay volume. The premium increases also drove many patients to less costly premiums associated with Bronze plans – which have a higher deductible, less coverage.
Federal Medicaid reimbursement reductions are slashing per-encounter revenue in both expansion and non-expansion states. As Medicaid revenue declines, the share of total revenue from patient responsibility increases, amplifying the financial impact of patient financing-structure decisions.
Under a recourse model, increased risk of default translates directly into increased contingent liability. The CFO , evaluating patient financing structure only through the lens of collections performance, is missing the balance-sheet risk that 2026 has made impossible to ignore.
Not all non-recourse patient financing platforms are structurally equivalent. CFOs evaluating vendors should look beyond the basic recourse vs non-recourse designation and apply the following criteria.
Verify the non-recourse structure is complete. Some arrangements described as non-recourse contain carve-outs for specific default categories, fraud events, or documentation failures that effectively restore recourse liability under certain conditions. Ask for the contract language governing recourse events and have legal counsel review it before signing.
Confirm the financing company’s source of capital and ability to provide a “revolving” line of credit to hundreds of thousands of patients enrolled. Many patient financing companies have access only to high-cost capital from PE firms, hedge funds, and other short-term, high-cost lenders. This arrangement makes it very difficult to provide a revolving line of credit that requires larger amounts of capital at a lower cost. They then offer a simple patient financing arrangement of balance-specific loans. Curae, a subsidiary of Atlanticus Holdings (Nasdaq:ATLC) with a $7B balance sheet, has institutional capital (e.g., pension funds) at a lower cost and in larger quantities. CURAEPay is a revolving line of credit provided at scale.
Evaluate the organization’s regulatory standing. A financing solution operating under federal banking regulations, specifically Regulation B (Equal Credit Opportunity Act) and Regulation Z (Truth in Lending Act), provides broad compliance coverage and great operational stability. Curae is a subsidiary of Atlanticus Holdings Corporation (Nasdaq: ATLC), regulated under both Reg B and Reg Z.
Confirm the pricing model is transparent. Health systems should review the approval rate for all patient applicants and the financing fees by patient risk tier. A successful program needs to approve financing for patients who would otherwise likely become bad debt. The program must include offers of 0% interest for up to a 24-month term and a choice of longer-term options.
Assess the implementation timeline against your revenue cycle calendar. Patient financing solutions require custom integration with patient access, EHR workflows, and patient billing/statements integration, as well as the patient portal/workflows integration. Sub-45-day implementation is achievable with modern API-integrated platforms and should be a baseline requirement in any vendor evaluation.
Evaluate brand impact alongside financial impact. A provider-branded (health system brand on the card and all related marketing materials) revolving line of credit builds patient loyalty to the health system and provides a desired retail-like experience. A third-party card product under the lender’s brand only does not encourage loyalty to any one organization. In an environment where patient retention and market share are C-suite priorities, the brand dimension of a financing platform is more than a marketing consideration. It is a strategic financial asset.
Improve Patient Financial Experience. Today’s patient wants a retail-like experience, including digital patient balance that’s understandable and financing to make care more affordable. CURAEPay offers one application to approve a revolving line of credit to handle today’s balance as well as tomorrow’s.
In healthcare, recourse debt means the health system retains contingent liability if patient accounts are not repaid, often requiring balance-sheet reserves and potentially triggering bond covenant restrictions that affect debt service coverage ratios and credit ratings. Non-recourse debt permanently transfers all repayment risk to the financing company at the moment of funding. The health system receives upfront revenue and has no further financial obligation related to that account, regardless of whether the patient repays.
Under GAAP, a health system with recourse-based patient financing may be required to recognize a contingent liability on its balance sheet equal to the estimated repurchase obligation associated with the non-performing portion of the financed portfolio. This reserve reduces net assets, affects debt-to-equity ratios, and can push a health system toward bond covenant thresholds it would otherwise clear. As patient default rates rise in response to higher deductibles and reduced ACA subsidies, the reserve required against a recourse portfolio increases, creating a growing balance-sheet liability from a financing arrangement that was intended to reduce financial risk.
Yes. Recourse-based financing arrangements pose two bond-covenant risks. First, the contingent liability and associated reserve requirements can reduce net assets and affect debt-to-equity ratios that bond covenants specify as minimum thresholds. Second, recourse repurchase obligations can create unpredictable cash outflows that reduce actual cash available for debt service below projected figures, affecting debt service coverage ratio calculations. For health systems with publicly issued debt, both risks should be evaluated before entering any recourse-based patient financing arrangement.
CURAEPay approves up to 90%+ of applying patients, including patients with limited or challenged credit histories. This is a key advantage over traditional financing models that may decline a larger share of applicants based on standard credit scoring.
Non-recourse patient financing converts patient receivables into immediate cash within 48 hours of account funding, with no subsequent cash outflow risk from recourse repurchase events. Because the financing company has assumed all credit risk, the health system’s cash position is not affected by patient default rates after funding. This creates predictable, immediate revenue recognition on patient balances that would otherwise sit in AR aging buckets for 90, 180, or 360 days, or never be recovered.
A patient financing platform that approves 60% of applicants has the potential to convert 60% of patient balances into funded receivables (to avoid bad debt). The remaining 40% will either enter collections, age into write-offs, or create charity care obligations. For a health system with $50 million in annual patient financial responsibility, the difference between a 60% approval rate or eligibility rate and a 90% approval rate/eligibility rate is $15 million in potential additional funded receivables per year.
Under GAAP, contingent liabilities must be recognized on the balance sheet when it is probable that a liability has been incurred, and the amount can be reasonably estimated. A recourse patient financing arrangement creates a contingent liability equal to the estimated repurchase obligation for the non-performing portion of the financed portfolio. The reserve methodology typically applies historical default rates to the outstanding recourse balance, with adjustments for current economic conditions. As patient default rates rise, the reserve increases, creating a growing balance-sheet liability that offsets the financing program’s revenue recovery benefit.
Regulation B, enacted under the Equal Credit Opportunity Act, prohibits discrimination in credit transactions and establishes requirements for adverse action notices when credit is denied. Regulation Z, enacted under the Truth in Lending Act, requires clear disclosure of credit terms, including APR, fees, and repayment schedules. Patient financing platforms operating under these federal regulations provide broader compliance coverage and greater operational stability than state-licensed lending arrangements. Health systems that partner with federally regulated financing companies reduce their compliance exposure on the patient credit dimension of their revenue cycle operations.
CURAEPay implements in under 45 days from contract execution to the first funded account. The model requires no custom software development, no EMR replacement, and no large upfront capital investment. It operates on a 100% contingency-based pricing model. Health systems begin generating net-positive returns quickly after go-live, with time-to-value measured in weeks rather than quarters.